# A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine

> **NCT01675284** · PHASE1 · COMPLETED · sponsor: **Medigen Biotechnology Corporation** · enrollment: 36 (actual)

## Conditions studied

- Bird Flu
- Avian Influenza
- Influenza A(H5N1)

## Interventions

- **BIOLOGICAL:** AT-301

## Key facts

- **NCT ID:** NCT01675284
- **Lead sponsor:** Medigen Biotechnology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-03
- **Final completion:** 2013-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01675284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01675284, "A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01675284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*